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Wound-Healing Studies in Transgenic and Knockout Mice
Richard Grose*,1,2 and Sabine Werner2
Injury to the skin initiates a cascade of events including inflammation, new tissue formation, and tissue
remodeling, that finally lead to at least partial reconstruction of the original tissue. Historically, animal
models of repair have taught us much about how this repair process is orchestrated and, over recent years,
the use of genetically modified mice has helped define the roles of many key molecules. Aside from conven-
tional knockout technology, many ingenious approaches have been adopted, allowing researchers to circum-
vent such problems as embryonic lethality, or to affect gene function in a tissue- or temporal-specific manner.
Together, these studies provide us with a growing source of information describing, to date, the in vivo
function of nearly 100 proteins in the context of wound repair.
This article focuses on the studies in which genetically modified mouse models have helped elucidate the
roles that many soluble mediators play during wound repair, encompassing the fibroblast growth factor
(FGF) and transforming growth factor-β (TGF-β) families and also data on cytokines and chemokines. Fi-
nally, we include a table summarizing all of the currently published data in this rapidly growing field. For a
regularly updated web archive of studies, we have constructed a Compendium of Published Wound Healing
Studies on Genetically Modified Mice which is avaialble at http://icbxs.ethz.ch/members/grose/
woundtransgenic/home.html.
Index Entries: Wound healing; mouse; gene targeting; growth factor; cytokine.
1. Introduction
Wound healing is a highly ordered and well-
coordinated process that involves inflammation,
cell proliferation, matrix deposition, and tissue re-
modeling (1). During the past few years, a series
of candidate key players in the wound-healing
scenario have been identified. These include not
only a variety of different growth factors and
cytokines, but also molecules that are involved in
cell–cell and cell–matrix interactions, and pro-
teins responsible for cell stability and cell migra-
tion. In most cases, the suggested function of
these molecules is based on descriptive expres-
sion studies and/or functional in vitro studies. By
contrast, their in vivo function in wound repair
has been poorly defined.
The development of transgenic mouse tech-
nologies has already provided new insights into
the function of many different genes during em-
bryonic development. These technologies allow
gain-of-function experiments (overexpression of
ligands and receptors) as well as loss-of-function
experiments (gene knockouts by homologous re-
combination in embryonic stem cells or overex–
pression of dominant-negative-acting molecules).
Although many unconditional knockout and
transgenic animals die during embryonic develop-
ment, spatial and temporal control of gene abla-
tion and overexpression, using both inducible and
cre-lox technologies, makes it possible to investi-
gate the functions of proteins formerly precluded
owing to developmental lethality. A large number
of viable genetically modified mice are now avail-
able that should not only be useful in determining
the role of the targeted or overexpressed genes in
normal physiology, but also for different types of
repair processes. Indeed, the past 5 yr have seen
an exponential growth in the number of transgenic
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mice used for wound-healing experiments, and
these studies have provided interesting and, in
many cases, unexpected results concerning the in
vivo function of growth factors, extracellular ma-
trix molecules, proteinases, and structural proteins
in wound repair. The list of transgenic wound-
healing studies continues to expand, and in an at-
tempt to retain an overview of the field, we have
therefore established a regularly updated Compen-
dium of Genetically Modified Mouse Wound Heal-
ing Studies available at http://icbxs.ethz.ch/
members/grose/woundtransgenic/home.html.
In this chapter, we focus on the studies in which
genetically modified mouse models have helped
elucidate the roles that many soluble mediators
play during wound repair. We begin by covering
the fibroblast growth factor (FGF) family, move
on to the transforming growth factor-β (TGF-β)
superfamily, and then address the data from
cytokine and chemokine studies. Finally, Table
1 summarizes all of the currently published data
in this rapidly growing field.
2. Fibroblast Growth Factors
FGFs comprise a growing family of structur-
ally related polypeptide growth factors, currently
consisting of 22 members (2). During embryo-
genesis, FGFs play key roles in regulating cell
proliferation, migration, and differentiation. In
adult tissues, FGFs have a diverse range of ef-
fects, including mediating angiogenesis and
neuroprotection, in addition to their stimulatory
effects during wound repair (3). FGFs transduce
their signals through four high-affinity transmem-
brane protein tyrosine kinases, FGF receptors 1–4
(FGFR1–4) (4). Many of the FGFs and their re-
ceptors show specific expression patterns in both
developing and adult skin (3), where they are par-
ticularly involved in the regulation of hair growth
(5). Being potent mitogenic and chemotactic fac-
tors, FGFs are clear candidates for contributing to
the wound-healing response. This hypothesis has
been corroborated by a number of studies in which
local application of FGFs stimulated tissue repair
(6).
2.1. Keratinocyte Growth Factor
2.1.1. Epidermal Expression of a Dominant-
Negative Keratinocyte Growth Factor Impairs
Wound Reepithelialization
Keratinocyte growth factor (KGF, FGF-7)
binds exclusively to a splice variant of FGF re-
ceptor 2 (FGFR2IIIb), a transmembrane protein
tyrosine kinase receptor that is present only on
epithelial cells (7). In previous studies, a strong
upregulation of KGF expression has been ob-
served after skin injury in mice and humans (8,9),
with mouse studies revealing KGF mRNA levels
more than 150-fold higher compared with the
basal levels at d 1 after injury (8). KGF expression
at the wound site is restricted to dermal fibroblasts
and γδ T cells, and, thus, it was hypothesized to act
in a paracrine manner, stimulating keratinocytes to
proliferate and migrate and thereby effect wound
reepithelialization. By targeting expression of
dominant-negative FGFR2IIIb to the epidermis, we
could block KGF receptor signaling at the wound
site and clearly demonstrate a reepithelialization
defect in transgenic mice. The mutant receptor
lacks a functional tyrosine kinase domain (10,11)
and, on ligand binding, forms nonfunctional
heterodimers with full-length wild-type recep-
tors, thereby blocking signal transduction (10–12).
The truncated form of the KGF receptor is known
to bind KGF; FGF-10; FGF-1; FGF-3; and, al-
though with lower affinity, FGF-2 (7,13,14).
Therefore, it should inhibit the action of all these
ligands.
Although the transgenic mice generated by
Werner et al. (15) appeared macroscopically nor-
mal, a histological analysis of their skin revealed
epidermal atrophy, disorganization of the epider-
mis, abnormal hair follicle morphology, and a 60–
80% reduction in the number of hair follicles.
Finally, these mice revealed dermal hyper-thick-
ening with a gradual replacement of adipose tis-
sue by connective tissue. Histological analysis of
full-thickness excisional wounds, where back skin
was excised to the level including the panniculus
carnosus muscle, revealed a severe delay in wound
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Table 1
Wound-Healing Studies on Transgenic and Knockout Micea
Gene Strategy Ref.
Activin A Overexpressor - Keratin 14 promoter (59)
BMP-6 Overexpressor - Keratin 10 promoter  (62)
BPAG1 Knockout  (85)
Cathepsin G Knockout  (86)
CD44 Antisense knockdown - Keratin 5 promoter  (87)
CDK4 Knockout  (115)
Connexin 30/31/43 Knockouts  (116)
CXCR2 Knockout  (75)
Cyr61 Knockout  (117)
E2F-1 Knockout  (118)
EGFR Knockout  (88)
FGF-1/2 Double knockout  (119)
FGF-2 Knockout  (27)
Fibrinogen Knockout  (89)
Fibrinogen Knockout  (120)
Plasma Fibronectin Knockout  (121)
Fibronectin EDA Knockout  (122)
Follistatin Overexpressor - Keratin 14 promoter  (123)
Glucocorticoid receptor Knock-in mutation  (124)
GM-CSF Overexpressor - Keratin 5 promoter  (125)
HGF Overexpressor - Metallothionein promoter  (126)
HGFL Knockout  (90)
Hoxb13 Knockout  (127)
β2-Integrin Knockout  (128)
β1-Integrin Conditional knockout - Keratin 5 Cre  (129)
β5-Integrin Knockout  (91)
Interleukin-6 Knockout  (66)
Interleukin-6 Knockout  (130)
Interleukin-10 Knockout  (77)
IP-10 Overexpressor - Keratin 5 promoter  (72)
c-Jun Conditional knockout - Keratin 14 Cre  (131)
c-Jun Conditional knockout - Keratin 5 Cre  (132)
Keratin 6a Knockout  (92)
Keratin 8 Knockout  (80)
KGF Knockout  (16)
KGFR Dominant negative - Keratin 14 promoter  (15)
Krox 24/20 Knockouts  (133)
MCP-1 / MIP-1α Knockout  (134)
MMP-1 Overexpressor - Haptoglobin promoter  (93)
MMP-3 Knockout  (94)
MMP-9 Knockout  (135)
c-Myc-ER Overexpressor - Keratin 14 promoter  (136)
Nf-1 Knockout  (95)
eNOS Knockout  (96)
iNOS Knockout  (97)
iNOS Knockout  (137)
NPY(2) receptor Knockout  (138)
Nrf-2 Knockout  (139)
(continued)
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Osteopontin Knockout  (98)
PAI-1 Knockout  (140)
PAI-1 Knockout  (141)
PAI-2 and PAI-1/2 Knockout / double knockout  (99)
PAR-1 Knockout  (100)
PDGF-B Knockout  (142)
PKC-ε Knockout  (143)
Placenta growth factor Knockout  (144)
Plasminogen Knockout  (101)
Plasminogen / Fibrinogen Double knockout  (89)
PPAR α and β Knockouts  (145)
PPAR β/δ Knockout  (146)
PU.1 Knockout  (147)
P and E Selectin Double knockout  (102)
Skn-1a/i Knockout  (103)
SLPI Knockout  (104)
Smad-3 Knockout  (54)
Smad-3 Knockout  (148)
Stat-3 Conditional knockout - Keratin 5 Cre  (68)
Syndecan-1 Knockout  (149)
Syndecan-4 Knockout  (105)
Tachykinin / Neurokinin-1 receptor Knockout  (150)
γ/δT cell receptor Knockout  (151)
Telomerase Overexpressor - Keratin 5 promoter  (152)
Tenascin C Knockout  (106)
TGFα Knockout  (153)
TGFα Knockout  (154)
TGFα Knockout  (155)
TGFα/KGF Double knockout  (16)
TGFβ Knockout  (40)
TGFβ Knockout  (46)
TGFβ Knockout  (156)
TGFβ Overexpressor - Albumin promoter  (47)
TGFβ Overexpressor - Keratin 14 promoter  (157)
TGFβ Overexpressor - Keratin 14 promoter  (158)
Type II TGFβ receptor Dominant negative - Keratin 5 promoter  (159)
Thrombomodulin Knockout  (107)
Thrombomodulin Overexpressor- Keratin 14 promoter  (108)
Thrombospondin-1 Overexpressor- Keratin 14 promoter  (109)
Thrombospondin-2 Knockout  (110)
TNF receptor p55 Knockout  (160)
tPA / uPA Double knockout  (111)
tPA / uPAR Double knockout  (112)
Transglutaminase-1 Knockout  (113)
Vimentin Knockout  (78)
Vitronectin Knockout  (114)
aRegularly updated version available at http://icbxs.ethz.ch/members/grose/woundtransgenic/home.html
Table 1 (continued)
Wound-Healing Studies on Transgenic and Knockout Micea
Gene Strategy Ref.
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reepithelialization in the transgenic mice compared
with control littermates (15). On d 5 after injury,
the number of proliferating keratinocytes in the
hyperproliferative epithelium was 80–90% reduced
compared with control mice. These results dem-
onstrated an important role for KGF receptor sig-
naling in wound repair, although the type of KGF
receptor ligand responsible for this defect was not
defined.
2.1.2. KGF-Deficient Mice Show No Defect
in Wound Healing
To determine further the role of KGF in devel-
opment and in repair processes, Guo et al. (16)
used embryonic stem cell technology to generate
mice lacking KGF. The obtained knockout mice
revealed no obvious defects, with the exception
of the fur, which appeared matted and greasy, es-
pecially in male animals. Although KGF is widely
expressed during development and in the adult
animal, no histological defects could be detected
in the KGF knockout mice. Most surprising, even
the healing process of full-thickness incisional
wounds was normal. Thus, no histological differ-
ences could be determined between normal mice
and those lacking KGF, and the proliferation rate
of the keratinocytes at the wound edge was not
altered. These data demonstrate that incisional
wounds can heal in the absence of KGF. It would,
however, be interesting to study the healing pro-
cess of excisional wounds in these animals, since
the extent of reepithelialization is much higher in
excisional than in incisional wounds.
The lack of obvious phenotypic abnormalities
in the KGF knockout mice is in contrast to the re-
sults obtained with the dominant-negative KGF
receptor (see this section, above). Although it
might be possible that KGF is indeed not involved
in these processes, this seems highly unlikely,
since the pattern of KGF expression correlates
very well with its postulated functions in normal
and wounded skin. The most likely explanation
for the discrepancies between the knockout and
the dominant-negative receptor results is a redun-
dancy in ligand signaling. Although KGF might
normally be the most important KGF receptor
ligand in normal and wounded skin, the lack of
this gene in KGF knockout mice might be com-
pensated for by other known KGF receptor ligands.
More recent data from our laboratory and from oth-
ers suggest that FGF-10 is the principal candidate
for effecting this compensation since it is also ex-
pressed in the mesenchyme of normal and wounded
skin (14,17). Studies using neutralizing KGF and/
or FGF-10 antibodies during wound repair should
help to clarify this issue further. Furthermore, the
tissue-specific knockout of the KGF receptor
splice variant of FGFR2 as well as double knock-
outs of different ligands of this receptor will shed
light on the role of the KGF receptor and the vari-
ous types of FGF in normal and wounded skin.
2.2. Wound Healing in Mice Deficient
in TGF-α
As already described, the inhibition of KGF re-
ceptor signaling in basal keratinocytes of transgenic
mice caused a severe delay in reepithelialization
(15). However, the wounds in these animals finally
healed (unpublished finding), demonstrating the
presence of other epithelial mitogens in the wound
that can at least partially compensate for the defect
in KGF receptor signaling. One of these factors
might be TGF-α, a strong mitogen and chemo–at-
tractant for many different cell types, including
epidermal keratinocytes (18). Furthermore, ex-
pression of TGF-α is strongly upregulated in the
wound tissue on d 1 after injury (16), and addi-
tion of exogenous TGF-α to a wound has been
shown to enhance epithelial wound healing (19).
To determine the role of endogenous TGF-α in
wound repair, two groups generated mice lacking
this growth factor (20,21). Surprisingly, these
mice appeared normal with the exception of eye
abnormalities and waviness of whiskers and fur.
By contrast, the epidermis of these mice was in-
distinguishable from that of control mice. Most
interestingly, no significant wound-healing abnor-
malities were observed in these mice, whereby
two different wound-healing models (full-thick-
ness back skin excisions and wounds generated by
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tail amputation) were used. However, one group
observed more variability in the rate of wound clo-
sure in TGF-α null mice (21), suggesting that the
lack of this mitogen can be compensated for to a
variable extent by other growth factors. Such a
compensation could be achieved by growth fac-
tors that, like TGF-α, bind to the epidermal
growth factor (EGF) receptor. The most likely
candidates are EGF and heparin-binding EGF,
which are present at high levels in wound fluid
(22). This hypothesis is supported by the severe
phenotypic abnormalities of mice lacking the EGF
receptor (23,24) and by transgenic mice express-
ing a dominant-negative EGF receptor in the epi-
dermis (25), although the wound-healing process
in these animals has not been analyzed yet. By
contrast, the lack of TGF-α is unlikely to be com-
pensated for exclusively by KGF, since incisional
wound healing also appeared normal in mice lack-
ing both TGF-α and KGF (16).
2.3. Mice Lacking FGF-2 Show Delayed
Reepithelialization
In contrast to the restricted pattern characteris-
tic of many of the FGFs, FGF-2 is expressed in
many different tissues and cell types. It exerts a
plethora of effects, both in vivo and in vitro, in-
cluding mitogenic, chemotactic, angiogenic, and
developmental activities. Thus, it is reported to act
as a survival factor in many models of tissue re-
pair, ranging from neural injury models to corneal
and skin wounds (26). Surprisingly, considering
the myriad of potential functions, mice lacking
FGF-2 appeared superficially indistinguishable
from wild-type littermates. However, when these
mice were challenged by full-thickness excisional
wounding, they showed delayed healing (27). In
addition to a retardation in the rate of
reepithelialization, mice null for FGF-2 show re-
duced collagen deposition at the wound site and
also have thicker scabs. Expression of FGF-2 is
known to be enhanced following injury (8,28), and
topical application of FGF-2 has been reported to
accelerate both dermal and epidermal repair (29–
31). In addition, neutralizing antibodies to FGF-2
were shown to inhibit granulation tissue forma-
tion in sponges implanted into rats (32). Taken
together, these findings suggest a specific role for
FGF-2 during wound healing that, despite the ap-
parent redundancy of FGF signaling, cannot be
covered for by other FGF family members.
3. TGF-β Superfamily Members and
Downstream Signaling Molecules
The TGF-β superfamily encompasses a diverse
range of proteins, many of which play important
roles during development and differentiation.
Mammalian members include TGF-β1-3, bone
morphogenetic proteins (BMPs), Mullerian inhib-
iting substance, inhibins, and activins (33). Their
biological effects are mediated by heteromeric re-
ceptor complexes, which signal via activation of
intracellular Smad signaling pathways (34). TGF-
β is one of the most studied molecules in the
wound-healing scenario. This growth and differ-
entiation factor is found in large amounts in plate-
lets and is also produced by several cell types that
are present in a wound, including activated mac-
rophages, fibroblasts, and keratinocytes (35).
Three TGF-β isoforms (TGF-β1, TGF-β2, and
TGF-β3) are present in mammals and have both
distinct and overlapping functions. In vitro, these
molecules have been shown to be mitogenic for
fibroblasts, but they inhibit proliferation of most
other cells. Furthermore, TGF-βs modulate differ-
entiation processes and are very potent stimula-
tors of the expression of extracellular matrix
(ECM) proteins and integrins (33). Therefore,
they have the properties expected of wound
cytokines. Indeed, a series of studies has demon-
strated a beneficial effect of exogenous TGF-β for
wound repair (35). Furthermore, endogenous
TGF-β is likely to play an important role in wound
healing, since all three types of mammalian TGF-
β are expressed during repair, with each isoform
having a characteristic distribution in the wound
tissue (36,37). TGF-β induction is modulated in a
complicated manner by systemic glucocorticoid
treatment of wild-type mice, suggesting that aber-
rant expression of TGF-β1, TGF-β2, and TGF-β3
is associated with the wound-healing defect seen
in these mice (37). Additionally, TGF-β is particu-
larly important for the scarring response; it has
been shown that TGF-β1 and TGF-β2 induce cu-
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taneous scarring, whereas TGF-β3 seems to in-
hibit this effect (38,39).
3.1. TGF-β1-Deficient Mice Show Severely
Impaired Late-Stage Wound Repair
To clarify further the role of the TGF-β1
isoform in wound repair, Brown et al. (40)
wounded transgenic mice deficient in TGF-β1
owing to a targeted disruption of the TGF-β1 gene
(41,42). These mice exhibit no obvious develop-
mental abnormalities and appear phenotypically
normal. However, at approx 3 wk of age, they de-
velop a severe wasting syndrome, which is accom-
panied by a pronounced multifocal inflammatory
response and tissue necrosis, resulting in multi-
system organ failure and death (41,42). To over-
come this problem, the animals were wounded at
d 10 after birth.
Full-thickness excisional wounds were created
on the backs of TGF-β1 null mice and control
mice and covered with a nonabsorbent dressing.
The percentage of wound closure was determined
at different time points after injury. Mice were
sacrificed at d 10 after wounding and the wounds
were analyzed histologically. Surprisingly, early
wound healing proceeded almost normally in the
TGF-β1-deficient mice, suggesting that other
TGF-β isoforms or even different growth factors
can compensate for the lack of TGF-β1 (40). Al-
ternatively, maternal rescue in utero by transpla-
cental transfer of TGF-β1 and postnatally by
transmission in the milk (43) might explain the
lack of abnormalities in early wounds. However,
the lack of TGF-β1 ultimately caused a severe in-
flammatory response in the wound, as well as in
many other tissues and organs, which is likely to
be responsible for the wound-healing abnormali-
ties seen at later stages. Thus, histological analy-
sis of the wounds at d 10 after injury revealed a
thinner, less vascular granulation tissue in the
knockout mice, which was dominated by a marked
inflammatory cell infiltrate. Furthermore, de-
creased reepithelialization and decreased collagen
deposition were observed in mutant animals when
compared with control mice (40). These defects
in wound repair are likely to be a secondary effect
of the severe wasting syndrome observed in these
mice. Malnutrition and weight loss have been as-
sociated with impaired wound healing (44,45),
and the weight loss that accompanies the inflam-
matory response is likely to exert an adverse ef-
fect on repair.
In summary, Brown et al. (40) demonstrated
that the lack of TGF-β1 can be compensated in
the early stage of wound repair. However, the se-
vere inflammation seen in the mice ultimately
caused a severe wound-healing defect.
3.2. Immunodeficient Mice Lacking
TGF-β1 Show Retarded Healing
To try to dissect the TGF-β1-dependent wound-
healing defects from the effects of severe inflam-
mation, Crowe et al. (46) crossed TGF-β1 null
mice onto the immunodeficient Scid–/– back-
ground (46). Scid–/– mice lack T- and B-cells and
therefore do not have the machinery to mount the
large inflammatory response seen in non-
immunocompromised mice lacking TGF-β1 (40).
In contrast to what was predicted, the absence of
inflammation in TGF-β1–/– Scid–/– mice resulted
in a major delay in all the primary phases of repair
by around a week compared to TGF-β1+/+ Scid–/–
controls. This delay was not singly owing to ei-
ther the lack of TGF-β1 or the lack of lympho-
cytes, but to the combination of the two. This
suggests that TGF-β1 and lymphocytes may af-
fect compensatory pathways during repair. Alter-
natively, the delay may be a side effect of the
absence of TGF-β1 in wounds leading to delayed
expression of the other two TGF-β isoforms, TGF-
β2 and TGF-β3. Although unable to distinguish
between which of these hypotheses may be true,
Crowe et al.’s (46) study presents an elegant
method for bypassing a knockout phenotype that
would otherwise mask a defect in wound repair.
3.3. Mice Overexpressing TGF-β1 Show
Severely Impaired Late-Stage Wound
Repair
In contrast to the knockout approaches de-
scribed above, Shah et al. (47) investigated the
effect of excess levels of TGF-β1 on wound re-
pair. Their hypothesis was that elevated levels of
circulating TGF-β1 would accelerate healing but
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also enhance scarring. Mice with elevated plasma
levels of active TGF-β1 were generated by cloning
a modified porcine TGF-β1 construct, generating
constitutively active TGF-β1, downstream of the
mouse albumin promoter region. Using a dorsal
incisional wounding model, complemented by ven-
tral subcutaneous implantation of polyvinyl alco-
hol (PVA) sponges, Shah et al. (47) were able to
study both normal cutaneous wound repair and cel-
lular infiltration as a model of granulation tissue
formation.
Surprisingly, they found that while the PVA
sponges yielded the expected results, with in-
creased cellularity, granulation tissue formation,
and collagen deposition in transgenic animals, lo-
cal TGF-β1 levels were lower in the incisional
wounds of transgenic mice than in their control
littermates. As such, the data show that increased
circulating levels of TGF-β1 do not necessarily
lead to increased levels of TGF-β1 at the wound
site. Concomitant with the decreased TGF-β1
level in transgenic wounds, an increase in levels
of TGF-β3 and type II TGF-β-receptor at the
wound site were observed, and this resulted in an
improved neodermal architecture in the healed
transgenic wounds.
3.4. Smad3 Null Mice Show Accelerated
Cutaneous Wound Healing With Increased
Rate of Reepithelialization and Reduced
Inflammation
TGF-βs and activin, both of which regulate key
cellular functions during cutaneous wound repair,
are known to require the nuclear transcriptional ac-
tivators Smad2 and Smad3 for their intracellular
signaling functions (48–50). Smad2 and Smad3
proteins are recruited to ligand-bound TGF-β and
activin receptor complexes, where they are phos-
phorylated by the type I receptor. The phosphory-
lated Smads 2 and 3 undergo a conformational
change, which allows them to bind to cytoplasmic
Smad4, after which they are able to translocate to
the nucleus and activate their downstream targets
(51).
In contrast to Smad2 null mice, which die dur-
ing embryogenesis (52), mice lacking functional
Smad3 survive into adulthood (53). Following
full-thickness incisional wounding, Smad3 null
mice show a marked augmentation in repair. This
accelerated healing was shown to be characterized
by an increased rate of reepithelialization and a
reduced local inflammatory infiltrate (54). In ad-
dition to neutrophils and monocytes being almost
absent in the Smad3 knockout wounds, there was
a dramatic decrease in granulation tissue forma-
tion, resulting in an overall decrease in wound
area. Wounds of Smad3 knockout mice were
found to have significantly lower levels of TGF-β
expression, likely owing to the decreased mono-
cyte concentration, since these cells form a major
supply line delivering TGF-β to the early wound.
To determine whether the lack of TGF-β was a
cause of rather than an effect of the lack of inflam-
matory response, exogenous TGF-β1 was applied
to the wounds of control and Smad3 null mice.
While this treatment resulted in an augmented neu-
trophil infiltration into the wounds of control mice,
it failed to rescue the inflammatory response in
Smad3 null animals, indicating that Smad3 signal-
ing may underpin TGF-β1-mediated inflammatory
cell chemotaxis. Contrastingly, exogenous TGF-β1
did rescue the granulation tissue phenotype, result-
ing in a stimulation of matrix production in the
wounds of Smad3 null mice, though the fibroblast
numbers were not increased. Thus, TGF-β1-depen-
dent matrix deposition seems to function in a
Smad3-independent fashion in these mice, in agree-
ment with previous studies suggesting a c-Jun-de-
pendent pathway (55).
Overall, the data suggest that Smad3 signaling
plays an inhibitory role during wound repair, since
its abrogation leads to enhanced reepithelialization
and contraction of wound areas, at least in an
incisional wound-healing scenario. As with the
KGF knockout mice, it would be interesting to see
how efficiently Smad3 null mice manage to repair
full-thickness excisional wounds, where the granu-
lation tissue formation is thought to play a more
important role.
3.5. Overexpression of Activin A in Basal
Keratinocytes Stimulates Wound Repair
Activin A, a TGF-β superfamily member, is a
homodimeric protein comprising two activin βA
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monomers connected by disulfide linkage. That it
might play a role in the skin was first suggested
by knockout mouse studies, of activin βA (56) and
of the activin antagonist follistatin (57), which
both showed clear phenotypes in hair follicle de-
velopment. Further studies from our laboratory
demonstrated activin βA to be strongly induced
following wounding (58). Therefore, mice
overexpressing the human activin βA chain in the
epidermis, under the control of the keratin 14 pro-
moter, were generated to further investigate its
role in tissue repair (59).
A study by Munz et al. (59) found that un-
wounded mice overexpressing activin displayed
epidermal hyperthickening and dermal fibrosis.
Following full-thickness excisional wounding, the
mice also showed enhanced granulation tissue for-
mation and more rapid wound reepithelialization
(Fig. 1). This augmentation of the granulation tis-
sue was accompanied by an earlier increase in ex-
pression of the ECM molecules fibronectin and
tenascin-C, although collagen expression remained
unaffected. Thus, in addition to revealing novel ac-
tivities of activin in keratinocyte differentiation and
dermal fibrosis, this study implicates activin as a
stimulatory factor during wound repair.
3.6. Epidermal Overexpression of BMP-6
Inhibits Wound Reepithelialization
BMP-6 is strongly expressed in the developing
murine epidermis, with mRNA levels falling after
6 d postpartum to a low level in adult skin (60).
As such, it is closely associated with the most ac-
tive phases of skin proliferation. To address fur-
ther the role of BMP-6 in the skin, Blessing et al.
(61) engineered transgenic mouse lines overex–
Fig. 1. Wound-healing phenotype of activin-overexpressing mice. Full-thickness excisional wounds were made
on the back of 3-mo-old female transgenic mice (wt/tg) and female control littermates (wt/wt). Mice were killed
on d 5 after injury. Sections (6 mm) from the middle of the wound were stained with hematoxylin and eosin. G,
granulation tissue; HE, hyperproliferative epithelium. Note the larger area of granulation tissue in the transgenic
mice. Magnification: ×25. (Reprinted from ref. 59. Copyright 1999 Oxford University Press.)
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pressing BMP-6 in the suprabasal layers of the
epidermis, using the keratin 10 promoter. Different
lines with varied patterns of transgene expression
showed completely opposite skin phenotypes.
Strong and uniform expression of the BMP-6
transgene inhibited cell proliferation but had little
effect on differentiation, whereas weak and patchy
expression evoked strong hyperproliferation and
parakeratosis in adult epidermis and severe per-
turbations of the usual pattern of differentiation,
resulting in a psoriasis-like phenotype.
Since BMP-6 was found to be upregulated in
human skin ulcers, where it may be involved in
the inhibition of reepithelialization, the same
laboratory decided to investigate wound repair
in these mice strongly overexpressing BMP-6
(62). Although all the major phases of tissue re-
pair could be observed in transgenic mice, they
showed significant delays in eschar detachment,
reepithelialization, and granulation tissue matu-
ration. Thus, BMP-6 may well be a causal factor
in the failure of repair seen in chronic wounds.
4. Cytokines and Chemokines
Cytokines are small, secreted proteins of up to
20 kDa that affect the behavior of immune cells as
well as other cells. They include the interleukins,
lymphokines, and several related signaling mol-
ecules, such as tumor necrosis factor-α (TNF-α),
TNF-β, and interferons. Chemokines are a subset
of cytokines that stimulate chemotaxis and ex-
travasation of immune cells via binding to G-pro-
tein-coupled receptors on the surface of target cells.
It has long been thought that the proinflammatory
cytokines, including interleukin-1α (IL-1α) and
IL-1β, IL-6, and TNFα, play an important role in
wound repair. They likely influence a series of
crucial biological effects at the wound site, includ-
ing stimulation of keratinocyte and fibroblast pro-
liferation, synthesis and breakdown of ECM
proteins, fibroblast chemotaxis, and regulation of
the immune response.
4.1. IL-6 Knockout Mice Show Severe
Deficits in Cutaneous Repair
IL-6 expression is rapidly upregulated follow-
ing wounding, being produced mainly by
keratinocytes, but also by macrophages, Langer-
hans cells, and fibroblasts (63). A mitogen for
keratinocytes (64), its overexpression is associ-
ated with several skin pathologies, including
psoriasis (65). Using a full-thickness punch bi-
opsy wounding model on IL-6 knockout mice,
Gallucci et al. (66) showed that IL-6 is essential
for reepithelialization, inflammation, and granu-
lation tissue formation.
Excisional wounds to IL-6 null mice took up to
three times longer to heal than those of wild-type
controls and were characterized by a dramatic de-
lay in reepithelialization and granulation tissue
formation. This impaired phenotype was com-
pletely rescued by administration of recombinant
murine IL-6 protein 1 h prior to wounding. Thus,
it appears that IL-6 is crucial for kick-starting the
wound response, both via its mitogenic effects on
wound edge keratinocytes and via its chemoat–
tractive effect on neutrophils, the first inflamma-
tory cells to reach the clot.
4.2. Stat-3-Mediated Transduction of IL-6
Signaling Is Essential for Tissue Repair
STATs (signal transducers and activators of
transcription) are cytoplasmic molecules that
transduce signals from a variety of growth factors,
cytokines, and hormones. Once activated by ty-
rosine phosphorylation, they dimerize and trans-
locate to the nucleus, where they bind to specific
DNA elements and thus activate target gene ex-
pression (67). Stat-3 is activated by IL-6 signal-
ing and is thus a likely candidate for a role in
wound repair. Since Stat-3 null mice die during
embryogenesis (68), Sano et al. (69) used a Cre-
lox approach to knock out Stat-3 in keratinocytes.
Consistent with a low level of IL-6 expression in
normal skin, they saw no effect on skin morpho-
genesis. However, following full-thickness
excisional wounding, the healing process was se-
verely compromised, with dramatically reduced
reepithelialization (Fig. 2), showing clear simi-
larities to the reepithelialization phenotype of the
IL-6 knockout mice. The overall effect on repair
was less dramatic than in the IL-6 null mice, since
the cell types involved in both the inflammatory
response and granulation tissue formation were
unaffected by the tissue-specific approach.
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4.3. Epidermal Overexpression
of IP-10 Delays Wound Repair
Interferon-γ-inducible protein-10 (IP-10) is a
chemokine that is detected at high levels in sev-
eral chronic inflammatory conditions, including
psoriasis. It is a member of the CXC family of
chemokines and acts primarily in the recruitment
of neutrophils and lymphocytes (70). It is also
one of a group of several chemokines that are
upregulated following wounding, with an ex-
pression pattern that correlates well with recruit-
ment of inflammatory cells to the wound site
(71). To determine whether IP-10 could modu-
late an in vivo inflammatory response, Luster et
al. (72) engineered mice that constitutively ex-
press IP-10 in keratinocytes. These mice showed
no obvious abnormalities, until they were sub-
jected to full-thickness excisional wounding.
Following injury, IP-10-overexpressing mice
showed a more intense inflammatory phase, de-
layed reepithelialization, and a prolonged, disor-
ganized granulation phase with impaired
angiogenesis compared with control littermates.
These data suggest that IP-10 is able to inhibit
wound repair by disrupting the normal develop-
ment of the granulation tissue.
4.4. CXCR2 Null Mice Show Multiple
Defects in Wound Healing
IP-10 exerts its biological effects via binding to
the CXCR3 chemokine receptor. This receptor is
reported to antagonize the signal transduction
pathway downstream of another chemokine re-
ceptor, CXCR2 (72). CXCR2 receptors are ex-
pressed on keratinocytes, neovascularizing
endothelial cells, and neutrophils and bind the
chemokines MIP-2 and KC, both of which are
upregulated in mouse wounds (73). To determine
their role in wound repair, Devalaraja et al. (74)
made full-thickness excisional punch biopsy
wounds in mice lacking CXCR2. Following
wounding, these mice exhibited defective neutro-
phil recruitment, delayed monocyte recruitment,
and decreased secretion of the proinflammatory
cytokine IL-1β. Histologically, they also showed
delayed reepithelialization and decreased
neovascularization (75).
4.5. IL-10 Causes Scarring in a Model
of Fetal Wound Repair
Fetal wound healing is characterized by rapid
reepithelialization, minimal inflammation, and
scar-free repair (76). Fetal wounds also show di-
minished expression of the proinflammatory
cytokines IL-6 and IL-8, a phenomenon that was
hypothesized to be owing to their negative regula-
tion by the anti-inflammatory cytokine IL-10. To
test this hypothesis, Liechty et al. (77) wounded
embryonic skin from IL-10 null mice that had
been grafted onto strain-matched adult mice.
Wounds of control embryonic skin grafts showed
little inflammation and normal restoration of der-
Fig. 2. Retardation of skin wound healing in Stat3-
disrupted mice. A comparison of skin wound healing
in a Stat3-disrupted mouse (–/–, right) and a control
littermate (+/+, left) is shown. The photograph was
taken on d 8 after wounding. (Figure courtesy of Prof.
Junji Takeda. Reprinted from ref. 69 by permission.
Copyright 1999 Oxford University Press.)
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mal architecture. However, wounded IL-10 null
grafts showed significantly higher inflammatory
cell infiltration and collagen deposition more akin
to the scarring associated with adult repair. This
study suggests that IL-10 plays an important role
in regulating the expression of proinflammatory
cytokines at the fetal wound site, and thus modu-
lates downstream matrix deposition that leads to
scar-free repair.
4.6. Embryo Studies Address Roles
for Intermediate Filaments in Wound Repair
In a further study into the mechanisms behind
the perfect healing that occurs in the embryo,
Eckes et al. (78) wounded midgestational mouse
embryos lacking the intermediate filament protein
vimentin. Embryonic day 11.5 mouse embryos are
capable of healing an excisional hind leg amputa-
tion wound within 24 h (79). Another study, using
the same model, had revealed that one of the ma-
jor intermediate filaments in early embryonic
skin, keratin 8, was not essential for normal em-
bryonic repair (80). Using DiI-labeling of wound
margin mesenchymal cells, Eckes et al. (78)
showed that, while reepithelialization proceeded
normally, vimentin null embryos failed to contract
the mesenchyme of their wound bed (Fig. 3).
Thus, vimentin is essential for the generation of
the tractional forces that drive mesenchymal con-
traction in the embryonic wound. This defect in
repair was also seen in adult wounds to vimentin
null mice, again in a defect limited to the connec-
tive tissue, which displayed delayed granulation
tissue formation and contraction.
5. Conclusion
Studies of wound healing using genetically
modified mice have already revealed crucial roles
for several genes in the repair process. However,
some of the normal functions of the genes targeted
might not be revealed owing to redundancy or
compensation. This hypothesis is supported by the
lack of obvious wound-healing abnormalities in
various knockout mice, such as mice deficient in
KGF or TGF-α (16). Although it cannot be ex-
cluded that these proteins are indeed not impor-
tant for wound repair, their strong induction in
healing skin wounds supports their functional sig-
nificance. In the case of TGF-α and KGF, other
growth factors, which bind to the same receptor,
might compensate for the lack of these mitogens.
Wound-healing studies using animals deficient in
two or more homologous molecules, as well as
studies with dominant-negative-acting molecules
that can inhibit the function of several members
of a protein family, will be very useful in answer-
ing these areas of question.
At the other extreme, secondary effects, which
are owing to systemic defects caused by the
transgene, or to transgene-mediated defects in
nonwounded skin, might obscure the normal func-
tion of a gene in wound repair. Thus, it has long
been known that the wound-healing process is sig-
nificantly impaired by systemic abnormalities
such as malnutrition, weight loss, impaired oxy-
genation, and ageing (44,45). This was also the
case in the TGF-β1 knockout mice, which devel-
oped a severe wasting syndrome at approx 3 wk
of age, accompanied by a severe inflammatory
response in various tissues and organs, including
the wound. These abnormalities are likely to be
responsible for the impaired wound healing seen
in these mice, making it impossible to study the
local effects of the lack of TGF-β1 on wound re-
pair in this model. One approach to circumvent
this problem, as mentioned under Subheading
3.2., was to cross the mice onto an immunodefi-
cient background. However, these problems might
also be solved by the generation of mice that have
a tissue-specific knockout or tissue-specific
overexpression of a transgene (81). Ideally, induc-
ible systems that allow the induction of a
transgene or the deletion of an endogenous gene
in a time- and tissue-specific manner should be
used. Such systems thus allow the study of the role
of a particular gene under specific conditions such
as during wound repair.
The first successful results with inducible sys-
tems in the skin have recently been published.
Two have adopted an estrogen receptor-based ap-
proach, where Cre recombinase was fused in
frame with the tamoxifen-responsive hormone-
binding domain of the estrogen receptor. This fu-
sion protein was expressed under the control of
the Keratin 5 promoter (82) or Keratin 14 pro-
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Fig. 3. Wound closure in wild-type and vimentin-deficient embryos. (A) Scanning electron micrograph of
embryonic d 11.5 mouse embryo with left hind limb bud amputated to leave oval-shaped excisional wound (ar-
rows). (B) Higher magnification detail of this 0-h wound. (C) After 24 h the wild-type wound is closed. (D) By
contrast, at 24 h postwounding the vimentin-deficient wound is still open. (E) Graphic representation of wound
closure (reepithelialization + connective-tissue contraction) as measured from scanning electron micrographs.
Shaded and solid symbols indicate area measurements in wild-type and vimentin-deficient embryos, respectively,
during the 24-h culture period. Error bars are SEMs. (F) Twenty-four hours postwounding, the wild-type controls
have significantly contracted their DiI-marked wound mesenchyme.(G) By contrast, at the same time point, the
vimentin-deficient wound has barely contracted. (H) Graphic representation of connective-tissue contraction com-
ponent of wound closure as measured from DiI-marked specimens. Shaded and solid symbols indicate area mea-
surements in wild-type and vimentin-deficient embryos, respectively, during the 24-h culture period. Error bars
are SEMs. Scale bars: (A) 1 mm; (B, C, D, F, G) 100 mm. (Figure courtesy of Dr. Paul Martin. Reprinted from ref.
78 by permission. Copyright 2000 Company of Biologists Ltd.)
moter (83). Cre-mediated recombination of loxP
sites flanking the target gene thus results in tem-
porally and spatially restricted knockout of the tar-
get gene. In a different approach, Wang et al. (84)
have used topical application of antiprogestin to
induce expression of target genes. This method
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works via skin-specific expression of a fusion pro-
tein, under the control of the loricrin promoter,
containing a truncated progesterone receptor
fused to the yeast GAL4 transcription factor.
Thus, by engineering a GAL4-binding domain,
normally absent in mammalian cells, upstream of
the target gene, transcription can be activated in a
tissue-specific and temporally controlled manner.
Use of these types of systems promises to yield
extremely valuable data on the actions of many
genes crucial to wound repair, but formerly im-
possible to study.
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